HistoSonics has officially launched Europe’s first Edison™ Histotripsy System at Addenbrooke’s Hospital, part of Cambridge University Hospitals NHS Foundation Trust, marking a major milestone in the global expansion of non-invasive tumor therapies. Powered by focused ultrasound energy, the Edison system mechanically destroys and liquefies targeted tissue—without incisions, radiation, or thermal damage. This breakthrough was made possible by a generous donation from the Li Ka Shing Foundation, which has long supported technological innovation in healthcare. The installation also received accelerated market access through the UK’s MHRA limited access program, enabling patients to benefit from this therapy sooner.

The Edison system’s primary clinical application is the non-invasive destruction of liver tumors, particularly in cases where surgery is not feasible. Unlike conventional therapies such as ablation or radiation, histotripsy avoids heat-related complications and spares surrounding tissue. The technology is already FDA-cleared in the U.S. and CE marking is underway to expand broader EU access. With active studies also targeting kidney and pancreas tumors, Edison represents a new category in tumor treatment—combining surgical precision with the safety and recovery profile of a non-invasive therapy. The system will be available to both NHS and private patients at Addenbrooke’s, enhancing care equity and clinical research in the UK.